Eleni Aklillu
About me
I am Professor of Global Health Pharmacology, Senior Research Scientist, and Leader of the Global Health Pharmacology and Therapeutics (GH-Pharma) Research Group at the Department of Global Public Health, Karolinska Institutet, Sweden. My research addresses major global health challenges affecting low- and middle-income countries, particularly in sub-Saharan Africa, with a focus on optimizing the prevention and treatment of infectious diseases. I investigate how genetic variation, drug-drug interactions, co-infections, comorbidities, nutrition, and environmental factors influence the safety, efficacy, and effectiveness of medicines, generating evidence that informs clinical practice, public health policy, and international treatment guidelines.
Over the past three decades, I have led multidisciplinary clinical research and capacity-strengthening programmes across Ethiopia, Kenya, Tanzania, Uganda, and Rwanda, addressing HIV/AIDS, tuberculosis, malaria, neglected tropical diseases, antimicrobial resistance, and maternal and child health. By integrating clinical pharmacology, neuropsychopharmacology, clinical trials, pharmacogenomics, pharmacokinetics/pharmacodynamics (PK/PD), drug-drug interaction studies, biomarker discovery, implementation science, pharmacovigilance, and regulatory science, my work has contributed to treatment optimization, evidence-based policy development, health systems strengthening, and the advancement of precision medicine.
Through multinational programmes funded by EDCTP, the European Union, Sida, and the Swedish Research Council, I have contributed to strengthening clinical trial infrastructure, pharmacovigilance systems, medicines regulation, research ethics, and regulatory science across Africa while fostering sustainable South-South and North-South partnerships. My research has supported the translation of scientific discoveries into policies and practices that improve patient care and public health outcomes.
A central component of my work is research capacity and institutional strengthening. I have supervised and mentored more than 30 PhD graduates, postdoctoral fellows, and early-career scientists, many of whom now hold leadership positions in universities, National Medicines Regulatory Authorities, WHO, Africa CDC, and public health programmes. To date, my research programmes have generated more than 190 peer-reviewed publications and contributed to building sustainable scientific leadership and research excellence across Africa.
Education- Postdoctoral Training in Clinical Pharmacology, Karolinska Institutet, Sweden
- PhD in Molecular Genetics, Karolinska Institutet, Sweden (2003)
- MSc in Biochemistry, Addis Ababa University, Ethiopia (1996)
- Bachelor of Pharmacy (B.Pharm), Addis Ababa University, Ethiopia (1987)
Selected Honours and Leadership Roles- Member, WHO-TDR Global External Review Group (since 2022)
- Member, WHO-TDR Scientific Working Group on Implementation Research (since 2021)
- Donald Mackay Medal (2020), awarded by the Royal Society of Tropical Medicine and Hygiene and the American Society of Tropical Medicine and Hygiene for outstanding contributions to tropical health
- Member, Committee for Development Research, Swedish Research Council (2016–2020)
- Vice-Chair and Member, Strategic Advisory Committee, EDCTP (2014–2018)
- Fellow of the Royal College of Physicians of Edinburgh (FRCP Edin) (2015)
- Fellow of the African Academy of Sciences (FAAS) (2015)
Funding
European Commission (Framework Programmes and Horizon Europe), EDCTP1, EDCTP2, Global Health EDCTP3, the Swedish Research Council, the Swedish Research Council for Sustainable Development (Formas), Sida bilateral research cooperation programmes, the Team Europe Initiative on Manufacturing and Access to Vaccines, Medicines and Health Technologies (TEI-MAV+), and International Vaccine Institute (IVI)I). As Principal Investigator or Coordinating Investigator, she has attracted more than SEK 300 million (approximately EUR 30 million) in externally funded research grants through competitive international and national funding schemes.Research Group Website: GH-Pharma Research Group
Research
- Research Areas: Global Health Pharmacology, Neuropsychopharmacology, Pharmacogenomics, Precision Medicine, Clinical Trials, HIV/AIDS, Tuberculosis, Malaria, Neglected Tropical Diseases, Antimicrobial Resistance, Maternal and Child Health, Pharmacovigilance, Regulatory Science, Implementation Science, and Health Systems Strengthening.
Clinical Pharmacology and Precision Medicine
- Pharmacogenomics of drug metabolism, efficacy, and toxicity
- Precision medicine and individualized therapy
- Pharmacokinetics/pharmacodynamics (PK/PD)
- Drug-drug interactions and treatment optimization
- Biomarker discovery and translational medicine
- Infectious disease pharmacology and therapeutics
- Antimicrobial resistance and antimicrobial stewardship
HIV/AIDS Research
- Optimization of antiretroviral therapy (ART)
- Pharmacokinetics and pharmacogenomics of ARVs
- HIV-TB co-treatment and integrated care
- Antiretroviral drug-drug interactions
- HIV treatment during pregnancy and breastfeeding
- Drug-induced toxicity, treatment safety, and long-term outcomes
Tuberculosis Research
- Optimization of TB-HIV co-treatment strategies
- Timing of ART initiation during TB treatment
- Pharmacokinetics and pharmacogenomics of anti-TB drugs
- Biomarkers of treatment response and toxicity
- Drug-resistant tuberculosis (MDR/RR-TB)
- Host-directed therapies and precision treatment approaches
Malaria Research
- Optimization of antimalarial treatment and prevention
- HIV-malaria drug interactions
- Pharmacogenomics of antimalarial treatment response
- Malaria prevention during pregnancy
- Safety, effectiveness, and implementation of malaria control interventions
Neglected Tropical Diseases (NTDs)
- Schistosomiasis, including female genital schistosomiasis
- Lymphatic filariasis and Onchocerciasis
- Soil-transmitted helminth infections
- Optimization of preventive chemotherapy and mass drug administration
- Safety monitoring and pharmacovigilance of NTD control and interventions
Maternal and Child Health
- Treatment optimization during pregnancy and lactation
- Maternal, fetal, and neonatal pharmacology
- Prevention and management of infectious diseases in pregnancy
- Medicine safety in mothers and children
Pharmacovigilance and Medicine Safety
- Post-marketing surveillance of medicines and vaccines
- Adverse drug reaction detection and monitoring
- Pharmacovigilance systems strengthening
- Signal detection, risk assessment, and risk management
- Active safety surveillance in resource-limited settings
Medicines Regulation and Regulatory Science
- Strengthening National Medicines Regulatory Authorities
- Regulatory systems and policy development
- Clinical trial oversight and regulatory review
- Research ethics and Good Clinical Practice (GCP)
- Regulatory science and evidence-based decision-making
- Regulatory capacity strengthening and regional harmonization in Africa
Research Capacity and Health Systems Strengthening- Clinical trial capacity development
- Research leadership and mentorship
- Implementation science and knowledge translation
- Health systems strengthening
- Pharmacovigilance and regulatory capacity development
- Sustainable Africa-Europe scientific partnerships and institutional strengthening
Articles
- Journal article: LANCET MICROBE. 2027;:101442Marais BJ; Goletti D; McHugh TD; Tiberi S; Aklillu E; Yeboah-Manu D; Mfinanga S; Zumla A; Ahmed R; Hasan T; Nyasulu PS; Chakaya J; Ntoumi F; Walzl G; Hui DS; Zumla A
- Article: JOURNAL OF INFECTIOUS DISEASES. 2026;:jiag377Zerebinski J; Broumou I; Kimenyi KM; Aklillu E; Andrade CM; Babiker H; Bejon P; Cherif MK; Crompton PD; Fancony C; Foroogh F; Gil JP; Homann MV; Trovoada MDJ; Kapulu M; Kiwuwa SM; Kweku MA; Liljander A; Lopes D; Marsh K; Mutemi DD; Ngasala B; Normark J; Orikiiriza J; Persson KEM; Portugal S; Ribacke U; Sirima SB; Sonden K; de Sousa TN; Traore B; Tijani MK; Eckerdal N; Villner P; Ochola-Oyier LI; Plaza DF; Farnert A
- Article: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2025;161:108118Namwase H; Mukonzo JK; Ankunda C; Vella S; Tadesse BT; Aklillu E
- Journal article: LANCET INFECTIOUS DISEASES. 2025;25(12):1336-1346van Eijk AM; Stepniewska K; Khairallah C; Rodriguez E; Ahn J; Gutman JR; Ter Kuile FO; IPTp-SP Effectiveness Study group
- Article: JOURNAL OF PUBLIC HEALTH RESEARCH. 2025;14(3):22799036251361622Tadele T; Astatkie A; Tadesse BT; Makonnen E; Abay SM; Aklillu E
- Article: INFECTIOUS DISEASES OF POVERTY. 2025;14(1):11Khaemba C; Njenga SM; Omondi WP; Kirui E; Oluka M; Guantai A; Aklillu E
- Article: BMC PUBLIC HEALTH. 2024;24(1):3367Gedefaw A; Tadesse BT; Tadesse S; Kebede B; Hussen S; Hailu D; Berhan Y; Makonnen E; Vella S; Aklillu E
- Article: DRUG SAFETY. 2024;47(12):1193-1202van Puijenbroek E; Barry A; Khaemba C; Ntirenganya L; Gebreyesus TD; Fimbo A; Minzi O; Makonnen E; Oluka M; Guantai A; Aklillu E
- Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2024;90(11):2823-2836Mugusi S; Mnkugwe RH; Sanga AA; Salahuddin A; Barclay V; Shayo G; Dahl M-L; Aklillu E
- Article: BMC INFECTIOUS DISEASES. 2024;24(1):901Gedefaw A; Tadesse BT; Berhan Y; Makonnen E; Vella S; Aklillu E
- Article: BMC PHARMACOLOGY & TOXICOLOGY. 2024;25(1):38Mlugu EM; Minzi OMS; Johansson M; Kamuhabwa AAR; Aklillu E
- Article: INFECTIOUS DISEASES OF POVERTY. 2024;13(1):44Fimbo AM; Mnkugwe RH; Mlugu EM; Kunambi PP; Malishee A; Minzi OMS; Kamuhabwa AAR; Aklillu E
- Article: SCIENTIFIC REPORTS. 2024;14(1):11730Gebreyesus TD; Makonnen E; Telele NF; Barry A; Mnkugwe RH; Gerba H; Dahl M-L; Aklillu E
- Article: INFECTIOUS DISEASES. 2024;56(4):308-319Sileshi T; Makonnen E; Telele NF; Barclay V; Zumla A; Aklillu E
- Article: INFECTIOUS DISEASES OF POVERTY. 2024;13(1):8Gebreyesus TD; Makonnen E; Tadele T; Mekete K; Gashaw H; Gerba H; Aklillu E
- Article: TROPICAL MEDICINE AND HEALTH. 2023;51(1):72Tadele T; Astatkie A; Tadesse BT; Makonnen E; Aklillu E; Abay SM
- Article: CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY. 2023;12(12):1884-1896Fimbo AM; Mlugu EM; Kitabi EN; Kulwa GS; Iwodyah MA; Mnkugwe RH; Kunambi PP; Malishee A; Kamuhabwa AAR; Minzi OM; Aklillu E
- Article: DRUG SAFETY. 2023;46(10):961-974Khaemba C; Barry A; Omondi WP; Kirui E; Oluka M; Parthasarathi G; Njenga SM; Guantai A; Aklillu E
- Article: PATHOGENS. 2023;12(9):1170Kabatende J; Ntirenganya L; Mugisha M; Barry A; Ruberanziza E; Bienvenu E; Bergman U; Aklillu E
- Article: SCIENTIFIC REPORTS. 2023;13(1):11438Sileshi T; Telele NF; Burkley V; Makonnen E; Aklillu E
- Show more
All other publications
- Editorial: LANCET INFECTIOUS DISEASES. 2025;25(10):1066-1068Ntoumi F; Aklillu E; Asogun D; Ansumana R; Mfinanga S; Yeboah-Manu D; Nacheg JB; Zumla A
- Preprint: BIORXIV. 2025Zerebinski J; Broumou I; Kimenyi KM; Aklilu E; Andrade CM; Babiker H; Bejon P; Cherif MK; Crompton PD; Fançony C; Foroogh F; Gil JP; Kapulu M; Kiwuwa SM; Kweku MA; Liljander A; Lopes D; Marsh K; Mutemi DD; Ngasala B; Normark J; Orikiiriza J; Persson KEM; Portugal S; Ribacke U; Sirima SB; Sondén K; de Sousa TN; Traore B; Tijani MK; Eckerdal N; Villner P; Ochola-Oyier LI; Plaza DF; Färnert A
- Editorial: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2025;155:107901Mpabalwani E; Ippolito G; Asogun D; Aklillu E; Maeurer M; Lee SS; Zumla A
- Review: ECLINICALMEDICINE. 2025;83:103202Roh ME; Gutman JR; Murphy M; Hill J; Madanitsa M; Kakuru A; Barsosio HC; Kariuki S; Lusingu JPA; Mosha F; Kajubi R; Kamya MR; Mathanga D; Chinkhumba J; Laufer MK; Mlugu E; Kamuhabwa AAR; Aklillu E; Minzi O; Okoro RN; Geidam AD; Ohieku JD; Desai M; Jagannathan P; Dorsey G; ter Kuile FO
- Review: IJID REGIONS. 2025;14(Suppl 2):100576Ahmed R; Zumla A; Taylor E; Aklillu E; Ippolito G; Satta G
- Book chapter: SPECIAL ISSUES IN PHARMACOVIGILANCE IN RESOURCE-LIMITED COUNTRIES. 2025;p. 365-371Aklillu E; Nderu M
- Editorial: LANCET INFECTIOUS DISEASES. 2025;25(1):14-16Sahu S; Ditiu L; Ahmed R; Zumla A; Aklillu E; Singh UB; Yeboah-Manu D; Asogun D; Hui DS; Zumla A
- Preprint: MEDRXIV. 2024;MEDRXIVRoh ME; Gutman J; Murphy M; Hill J; Madanitsa M; Kakuru A; Barsosio HC; Kariuki S; Lusingu JPA; Mosha F; Kajubi R; Kamya MR; Mathanga D; Chinkhumba J; Laufer MK; Mlugu E; Kamuhabwa AAR; Aklillu E; Minzi O; Okoro RN; Geidam AD; Ohieku JD; Desai M; Jagannathan P; Dorsey G; Ter Kuile FO
- Letter: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2024;80(7):1111-1112Stingl J; Aklillu E; Masimirembwa C; Kek TL
- Review: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2024;141:107002Petersen E; Al-Abri S; Al-Jardani A; Memish ZA; Aklillu E; Ntoumi F; Mwaba P; Wejse C; Zumla A; Al-Yaquobi F
- Conference publication: BMJ GLOBAL HEALTH. 2023;8(SUPPL_10):a37.3-a3a38Khaemba C; Barry A; Omondi W; Kirui E; Mandale M; Oluka M; Gurumurthy P; Njenga S; Guantai A; Aklillu E
- Conference publication: BMJ GLOBAL HEALTH. 2023;8(SUPPL_10):a35.2-a3a35Fimbo AM; Minzi O; Aklillu E
- Conference publication: BMJ GLOBAL HEALTH. 2023;8(SUPPL_10):a32.1-a3a32Gebreyesus TD; Makonnen E; Tadele T; Mekete K; Gashaw H; Gerba H; Aklillu E
- Conference publication: BMJ GLOBAL HEALTH. 2023;8(SUPPL_10):a78.1-a7a78Tadesse BT; Birhan Y; Mekonnen E; Vella S; Aklillu E; Gedefaw A
- Editorial: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2023;131:180-182Petersen E; Hui DS; Nachega JB; Ntoumi F; Goletti D; Aklillu E; Sharma A; Nyirenda T; Yeboah-Manu D; Satta G; da Costa C; Azhar EI; Bockarie M; Al-Abri S; Mchugh TD; Rodriguez-Morales AJ; Varghese G; Zumla A
- Review: PHARMACOGENOMICS & PERSONALIZED MEDICINE. 2022;15:561-571Sileshi T; Mekonen G; Makonnen E; Aklillu E
- Editorial: LANCET RESPIRATORY MEDICINE. 2022;10(6):533-536Castro KG; Ditiu L; Sahu S; Ntoumi F; Tiberi S; O'Kane CM; Akkerman O; Manika K; Mwaba P; Forsman LD; Petersen E; Aklillu E; Azhar EI; Cirillo DM; Migliori G-B; Abbara A; Zumla A
- Editorial: LANCET INFECTIOUS DISEASES. 2022;22(4):442-444Ntoumi F; Nachega JB; Aklillu E; Chakaya J; Felker I; Amanullah F; Yeboah-Manu D; Castro KG; Zumla A
- Editorial: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. 2022;114:268-272Petersen E; Ntoumi F; Hui D; Abubakar A; Kramer LD; Obiero C; Tambyah PA; Blumberg L; Yapi R; Al-Abri S; Pinto TDCA; Yeboah-Manu D; Haider N; Asogun D; Velavan TP; Kapata N; Bates M; Ansumana R; Montaldo C; Mucheleng'anga L; Tembo J; Mwaba P; Himwaze C; Hamid MMA; Mfinanga S; Mboera L; Raj T; Aklillu E; Veas F; Edwards S; Kaleebu P; McHugh TD; Chakaya J; Nyirenda T; Bockarie M; Nyasulu PS; Wejse C; Muyembe-Tamfum J-J; Azhar EI; Maeurer M; Nachega JB; Kock R; Ippolito G; Zumla A
- Review: EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY. 2021;17(9):1125-1138Aklillu E; Engidawork E
- Show more
Grants
- European Commission1 July 2024 - 30 June 2027Why RER-CTO?: The conduct of clinical trials requires competent ethics committee and regulatory authorities that can review clinical trial applications and monitor processes independently and efficiently ensuring the safety of clinical trial participants, and the integrity and reliability of the generated data. The capacity of most African regulatory authorities regarding clinical trial review and oversight is weak due to poor infrastructure, limited resources both human and financial, lack of expertise, un-conducive working framework and lack of systems adequately supported by technology. Collaboration between academia, international organizations, National ethics committees (NECs) and national regulatory authorities (NRAs) are mandatory to produce sustainable regulatory skills and functional clinical trial oversight systems. The RER-CTO consortium consists of a group of well reputable clinical trial researchers, regulatory authorities, ethics committees, universities and research institutes in Ethiopia, Tanzania, Norway, and Sweden. Our aim is to achieve ethics and regulatory excellence and harmonization in sub-Saharan Africa in clinical trial oversight (CTO) by improving the legal and policy framework by identifying gaps and making recommendations, improving regulatory and research ethics oversight capacity and capability by digitalising the clinical trial oversight systems and developing training programs to strengthen competency of relevant stakeholders, and strengthening local, regional, and international collaborations and coordination of NECs and NRAs for clinical trial oversight by developing joint clinical trial review guidelines. These efforts are geared towards increasing clinical trials in sub-Saharan Africa, standardization of clinical trial review and monitoring processes, and promoting ownership, efficiency, linkages for data sharing, transparency, and accountability of clinical trial review processes.
- Global Health EDCTP3 Joint Undertaking11 June 2024 - 10 June 2027Africa’s regulatory authorities lack the resources and infrastructure to oversee clinical trials effectively. To address these challenges and improve oversight systems, collaboration between academia, international organisations, national ethics committees, and regulatory authorities is essential. The EU-funded RER-CTO project aims to enhance ethical and regulatory standards for trial oversight (CTO) in sub-Saharan Africa. It focuses on identifying gaps in the legal and policy framework, improving regulatory and research ethics oversight capacity through the digitalisation of CTO systems, developing training programmes, and fostering collaboration among NECs and NRAs to create joint clinical trial review guidelines. The project involves clinical trial researchers, regulatory authorities, ethics committees, universities, and research institutes from Ethiopia, Tanzania, Norway, and Sweden.
- Global Health EDCTP3 Joint Undertaking1 June 2024 - 31 May 2026
- European Commission1 June 2023 - 31 May 2026
- The European and Developing Countries Clinical Trials Partnership (EDCTP)1 June 2018 - 31 December 2025
- European & Developing Countries Clinical Trials Partnership1 March 2018 - 31 August 2024
- Swedish Research Council1 January 2016 - 31 December 2019
- Swedish Research Council1 January 2012 - 31 December 2014
- Swedish Research Council1 January 2012 - 31 December 2014
- Swedish Research Council1 January 2010 - 31 December 2012
Employments
- Professor, Tropical Pharmacology, Department of Global Public Health, Karolinska Institutet, 2023-
- Professor, ME Infektion, Karolinska Universitetssjukhuset, 2023-
- Professor, Tropical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, 2020-2023
Degrees and Education
- Docent, Karolinska Institutet, 2009
- Doctor Of Philosophy, Institute of Environmental Medicine, Karolinska Institutet, 2003
Leadership and responsibility assignments
- Research team leader, Global Health Pharmacology and Therapeutics (GH-Pharma) – Eleni Aklillu's research group, Department of Global Public Health, Karolinska Institutet, 2023-
Supervision
Supervision to doctoral degree
- Christabel Khaemba, Pharmacovigilance in mass drug administration for the control and elimination of lymphatic filariasis in Kenya, 2024
- Adam Mitangu Fimbo, Pharmacovigilance of mass drug administration as preventive chemotherapy to control and eliminate lymphatic filariasis in Tanzania, 2024
- Tigist Dires Gebreyesus, Pharmacovigilance of preventive chemotherapy for the control of schistosomiasis and soil-transmitted helminths in Ethiopia, 2023
- Joseph Kabatende, Pharmacovigilance of mass drug administration for the control of schistosomiasis and soil transmitted helminths in Rwanda., 2023
- Abbie Barry, Pharmacovigilance capacity in East Africa with focus on neglected tropical diseases., 2022
- Rajabu Hussein Mnkugwe., Novel combination chemotherapy for treatment and control of schistosomiasis among school children., 2021
- Eulambius Mathias Mlugu, Optimization of intermittent preventive therapy for malaria during pregnancy: effectiveness of dihydroartemisinin-piperaquine versus sulfadoxine-pyrimethamine., 2021
- Birkneh Tilahun Tadesse, Optimization of pediatrics antiretroviral treatment outcomes among HIV infected children in Ethiopia., 2020
- Fazleen Haslinda Mohd Hatta, The impact of genetics, environmental, and geographical factors on inter-individual and inter-ethnic differences in CYP2C9-catalysed drug metabolism, 2015
- Wondwossen Amogne Degu, Optimization of TB/HIV co-treatment in Ethiopian patients, 2015
- Eliford Ngaimisi Kitabi, Optimization of HIV and tuberculosis co-treatment in Tanzanian patients: emphasis on pharmacogenetics and drug interactions, 2013
- Abiy Habtewolde Eyakem, Pharmacokinetic and Pharmacogenetic aspects of drug-drug interactions between antiretroviral and anti-tuberculosis drugs in Ethiopian patients: Implication for optimization of TB-HIV co-treatment., 2013
- Sabina Mugusi, Optimization of HIV and tuberculosis co-treatment in Tanzania: drug-drug interactions and clinical outcomes., 2013
- Getnet Yimer Ali, Incidence, predictors and biomarkers for antiretroviral and/or anti-tuberculosis drugs induced liver injury., 2012
- Natasa Djordjevic, Importance of pharmacogenetic and environmental factors for variation in caffeine disposition: with special emphasis on CYP1A2, CYP2A6, NAT2 and XO., 2012
- Jackson Mukonzo., Pharmacogenetic aspects of HIV/AIDS, tuberculosis and malaria: emphasis on Ugandan population., 2011
- Annika Allqvist, The role of CYP3A4/5 in alprazolam metabolism., 2010
- Roza Ghotbi, Genetic, epigenetic and environmental factors of importance for CYP1A2 catalyzed drug metabolism., 2008
Supervision to licentiate degree